Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | KIF11 | P52732 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19020520 | 0.80 | TP53 (0.48) | TP53KIF11MEN1KMT2ARAB9A | |
| SCHEMBL23098272 | 0.80 | TP53 (0.48) | TP53KIF11MEN1KMT2ARAB9A | |
| SCHEMBL8973 | 0.79 | KIF11 (0.48) | KIF11ALDH1A1CYP1A2KCNN4MAPK1 | |
| SCHEMBL6546659 | 0.78 | TP53 (0.56) | TP53KIF11MEN1KMT2ARAB9A | |
| SCHEMBL10635256 | 0.78 | TP53 (0.56) | TP53KIF11MEN1KMT2AALDH1A1 | |
| SCHEMBL24767488 | 0.78 | KIF11 (0.53) | TP53KIF11MEN1KMT2AMAPK1 | |
| SCHEMBL11432250 | 0.78 | MAPK1 (0.68) | TP53KIF11MEN1KMT2ARAB9A | |
| SCHEMBL11862313 | 0.77 | TP53 (0.54) | TP53KIF11MEN1KMT2ARAB9A | |
| SCHEMBL17753725 | 0.77 | TP53 (0.54) | TP53KIF11MEN1KMT2ARAB9A | |
| Ammonia Solution, Strong SCHEMBL23726528 | 0.77 | KIF11 (0.46) | KIF11ALDH1A1CYP1A2KCNN4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114950159-A | Preparation method of aromatic polymer separation membrane based on super-acid catalysis preparation | 南京工业大学 | 2022-08-30 | — | — | CN | claimed |
| CN-114950159-B | Preparation method of aromatic polymer separation membrane based on super acid catalysis | 南京工业大学 | 2023-06-06 | — | — | CN | disclosed |
| CN-114950159-A | Preparation method of aromatic polymer separation membrane based on super-acid catalysis preparation | 南京工业大学 | 2022-08-30 | — | — | CN | disclosed |
| US-10633408-B2 | Nucleoside-lipid compounds with pH-sensitive dialkylorthoester chains and their use for transportation or vectorization of at least one therapeutic agent | Universite de Bordeaux (FR) | 2020-04-28 | — | — | US | disclosed |
| EP-3298023-B1 | NUCLEOSIDE-LIPID COMPOUNDS WITH PH-SENSITIVE DIALKYLORTHOESTER CHAINS AND THEIR USE FOR TRANSPORTATION OR VECTORIZATION OF AT LEAST ONE THERAPEUTIC AGENT | UNIV BORDEAUX (FR) | 2019-07-10 | — | — | EP | disclosed |
| US-20180118775-A1 | Nucleoside-lipid compounds with pH-sensitive dialkylorthoester chains and their use for transportation or vectorization of at least one therapeutic agent | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2018-05-03 | — | — | US | disclosed |
| EP-3298023-A1 | NUCLEOSIDE-LIPID COMPOUNDS WITH PH-SENSITIVE DIALKYLORTHOESTER CHAINS AND THEIR USE FOR TRANSPORTATION OR VECTORIZATION OF AT LEAST ONE THERAPEUTIC AGENT | Université de Bordeaux (FR) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016188868-A1 | NUCLEOSIDE-LIPID COMPOUNDS WITH PH-SENSITIVE DIALKYLORTHOESTER CHAINS AND THEIR USE FOR TRANSPORTATION OR VECTORIZATION OF AT LEAST ONE THERAPEUTIC AGENT | Universite de Bordeaux (FR) | 2016-12-01 | — | — | WO | disclosed |
| EP-3095790-A1 | NUCLEOSIDE-LIPID COMPOUNDS WITH PH-SENSITIVE DIALKYLORTHOESTER CHAINS AND THEIR USE FOR TRANSPORTATION OR VECTORIZATION OF AT LEAST ONE THERAPEUTIC AGENT | UNIVERSITE DE BORDEAUX (FR) | 2016-11-23 | — | — | EP | disclosed |
| EP-0649411-A4 | BORONATED COMPOUNDS. | BORON BIOLOG INC (US) | 1995-07-12 | — | — | EP | disclosed |
| EP-0649411-A1 | BORONATED COMPOUNDS | BORON BIOLOGICALS, INC. (US) | 1995-04-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633408-B2 | Nucleoside-lipid compounds with pH-sensitive dialkylorthoester chains and their use for transportation or vectorization of at least one therapeutic agent | SLC29A2, SLC29A1, SAMHD1 | TP53 4738/4885KIF11 2333/4885MEN1 2593/4885 |
| US-20180118775-A1 | Nucleoside-lipid compounds with pH-sensitive dialkylorthoester chains and their use for transportation or vectorization of at least one therapeutic agent | SLC29A2, SLC29A1, SAMHD1 | TP53 4738/4885KIF11 2333/4885MEN1 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.